Figure 6

Survival and organ infiltration in the post-implantation model of disseminated MCL. (A) Anti-human CCR7 mAb significantly increases the survival of xenografted mice. Kaplan-Meier analysis of overall survival of mice treated with the anti-CCR7 mAb. Granta-519 cells were implanted intravenously in the vein tail of NOD/SCID mice (n = 15). Treatment with 200 μg of either the anti-CCR7 mAb or its corresponding isotype control or with PBS started at day 7 post-inoculation and continued at days 11 and 15. Anti-CCR7 mAb were administered intraperitoneally. P-value refers to the differences of the survival of PBS-, IC- and anti-CCR7-treated groups (B) Anti-human CCR7 mAb significantly reduces the infiltration of distant organs in the post-implantation model. Immunohistochemistry analyses were performed in tissue sections from brain, spine and lungs using anti-human CD20 mAb. Representative pictures from both a control mouse and an anti-CCR7 treated mouse are shown.